Story perspectives

Earendil Labs Raises $787M to Advance AI Biologic Medicines

3/21/2026

Summary

Story summary

Earendil Labs secured $787 million in funding from investors including Sanofi to scale AI-driven biologic medicines for autoimmune conditions and cancer and to advance programs toward clinical testing, according to Jian Peng.
The company, rooted in China and based in the United States, has over 40 programs, with 19 in its pipeline, including inflammatory bowel disease and lung cancer.
Earendil Labs is considering an initial public offering in Hong Kong.

1 of 1

Story summary

Earendil Labs secured $787 million in funding from investors including Sanofi to scale AI-driven biologic medicines for autoimmune conditions and cancer and to advance programs toward clinical testing, according to Jian Peng.
The company, rooted in China and based in the United States, has over 40 programs, with 19 in its pipeline, including inflammatory bowel disease and lung cancer.
Earendil Labs is considering an initial public offering in Hong Kong.